Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.
A space ETF built its entire pitch around getting retail investors into SpaceX before the IPO. Then SpaceX went public, and suddenly the fund had to justify its existence on completely different terms.
OpenAI’s annualized revenue has topped $40 billion, roughly double its level at the end of 2025, with President Greg Brockman saying the run rate jumped more than 20% in July alone. The surge comes just as the price of AI...
Even after its recent rally, there could be more meaningful gains ahead for SpaceX.
Workday stock surged after a report of a possible takeover by private equity firm Silver Lake.
Workday stock jumped on Thursday after a published report that private-equity firm Silver Lake is in talks to acquire the enterprise software company. According to the Reuters report, which cited people familiar with the matter, Silver Lake and Workday have held discussions about a possible deal in recent months. Barron’s has reached out to Workday and Silver Lake for comment.
Investors believe Anthropic could target an IPO valuation north of $2 trillion, according to the Financial Times.
The company's bulls believe this may be the start of a sustained run.
Adyen, the Dutch firm that handles payments for Spotify and Microsoft, raised its annual revenue growth forecast on Thursday as it continued to win more customers and invest in its payments technology. Adyen now expects net revenue to grow between 21% and 23% in 2026, compared with a previous range of 20% to 22%. Half-year adjusted core earnings reached €641.5 million, against analysts' estimate of €647.2 million, reflecting higher costs from its recent acquisitions.
A Chinese humanoid maker just pulled off one of the most frenzied IPOs in recent memory, and the shockwaves are now rippling through U.S. robotics stocks in a big way. Here is what traders are watching as the physical AI theme hits a new gear.
Anthropic is racing toward a public debut in September with a healthcare AI pitch that could ignite a sector most investors are not watching. Five biotech names are already moving, and one has climbed nearly 400% in the past year alone.
OpenAI has reportedly completed a deal to help employees sell nearly $7 billion worth of the company’s shares ahead of its potential IPO. The Sam Altman-led company repurchased shares from existing as well as former employees rather than relying on...
Ark Invest on Monday said that SPCX’s 14% drop on Wednesday last week overlooked SpaceX’s $28.5 trillion total addressable market outlined in its IPO filings.
Initial public offerings won't unlock instant wealth for retail investors.
The newly public companies offer investors a choice between the hot space sector and the emerging quantum computing market.
Loar stock sets up a new buy point amid the recent market strength. The aerospace and defense giant is looking for support at a key level.
Wall Street Says AMD's Taalas Deal Won't Close Nvidia's AI Gap
(Bloomberg) -- Latigo Biotherapeutics Inc., a clinical-stage developer of non-opioid pain medicines, climbed 17% on Friday after raising $345.6 million in an upsized initial public offering, priced at the top of a marketed range.Most Read from BloombergOpenAI’s New Device Will Be Hockey Puck-Sized and Cost Over $300Iran Wants to Bar US, Israeli Ships From Hormuz in Peace AccordIran Says Agreement on Hormuz Shipping Reached With OmanTrump Administration Considers Order on Autism and VaccinesWhy D
Stock market leaders are becoming plentiful as the S&P 500 probes all-time highs. Recent IPO Bending Spoons clears an IPO base.
SPCX stock climbed 6% on Thursday despite 911.5 million shares becoming eligible for sale after a lockup expired.
Investing.com -- Roku Inc (NASDAQ:ROKU) reported second quarter results that exceeded analyst expectations, with adjusted earnings per share of $1.08 compared to the consensus estimate of $0.60, and revenue of $1.35 billion versus the $1.3 billion estimate.
AstraZeneca (NASDAQ: AZN) and Bristol Myers Squibb (NYSE: BMY) are the two directly affected public companies; AZN bears the most immediate price risk given it absorbed a roughly 9% single-day selloff on Monday when the merger speculation first emerged, while BMY shareholders were widely viewed as the primary beneficiaries of any combination.
Is Chipotle facing another food safety crisis?
The Ark Invest founder is betting big on SpaceX.
Suze Orman walked through a real SpaceX IPO trade that turned $10,000 into roughly $5,600 in seven weeks, and her lesson has nothing to do with rockets or Elon Musk.
Bristol Myers Squibb stock is surging Monday following a report of a potential mega-merger with a competitor.
Which of these three high-tech market newcomers is the best?
Is the hot IPO stock finally a bargain?
Video podcasting and gaming could be revenue generators for Netflix, but there isn't anything on the immediate horizon to help reverse stock price losses.
The new CEO took over the conglomerate with a massive nest egg that he must try to deploy.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
